{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T23:04:10Z","timestamp":1776380650539,"version":"3.51.2"},"reference-count":24,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Prophylactic treatment with emicizumab has become an important and effective bleeding prevention for people with hemophilia A (PwHA). Perioperative management of PwHA using emicizumab prophylaxis is still challenging due to a lack of experience. Medical records of perioperative management and outcomes were reviewed, and data were collected for adult PwHA receiving emicizumab and undergoing surgical procedures between August 2019 and July 2022 at the University Medical Center Ljubljana. Twelve surgical procedures were performed in eight PwHA (one with FVIII inhibitors) while on emicizumab prophylaxis. Three minor procedures included cataract surgery, cystoscopic lithotripsy, and percutaneous coronary intervention. Nine major surgeries included four osteosyntheses, necrectomy of chronic osteomyelitis with new ankle arthrodesis, two below-knee amputations, total knee replacement, and placement of ventriculostomy after a spontaneous intraventricular hemorrhage. No major bleeds, thrombotic events or deaths, or new inhibitors appeared. Our real-world experience demonstrates that minor and major surgeries can be performed safely in PwHA on emicizumab prophylaxis. Additional data are needed to optimize dosing\/duration of additional hemostatic agents in diverse invasive procedures and complex clinical situations.<\/jats:p>","DOI":"10.3390\/hematolrep15040062","type":"journal-article","created":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T03:29:33Z","timestamp":1698809373000},"page":"597-607","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Management and Outcomes of Invasive Procedures in Individuals with Hemophilia A on Emicizumab Prophylaxis: A Single Center Experience"],"prefix":"10.3390","volume":"15","author":[{"given":"Karla","family":"Rener","sequence":"first","affiliation":[{"name":"Department of Hematology, University Medical Center Ljubljana, Zalo\u0161ka cesta 7, 1000 Ljubljana, Slovenia"},{"name":"Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sa\u0161a","family":"An\u017eej Doma","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Medical Center Ljubljana, Zalo\u0161ka cesta 7, 1000 Ljubljana, Slovenia"},{"name":"Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Fink","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Medical Center Ljubljana, Zalo\u0161ka cesta 7, 1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3752-2067","authenticated-orcid":false,"given":"Helena","family":"Podgornik","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Medical Center Ljubljana, Zalo\u0161ka cesta 7, 1000 Ljubljana, Slovenia"},{"name":"Faculty of Pharmacy, University of Ljubljana, A\u0161ker\u010deva cesta 7, 1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irena","family":"Prelo\u017enik Zupan","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Medical Center Ljubljana, Zalo\u0161ka cesta 7, 1000 Ljubljana, Slovenia"},{"name":"Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/bjh.15745","article-title":"Haemophilia and ageing","volume":"184","author":"Shapiro","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood-2015-06-650226","article-title":"A first-in-human phase 1 study of ACE910, a novel factor VIII\u2013mimetic bispecific antibody, in healthy subjects","volume":"127","author":"Uchida","year":"2016","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/hae.14372","article-title":"Adoption of emicizumab (Hemlibra\u00ae) for hemophilia A in Europe: Data from the 2020 European Association for Haemophilia and Allied Disorders survey","volume":"27","author":"Krumb","year":"2021","journal-title":"Haemophilia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/hae.13495","article-title":"Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee","volume":"24","author":"Collins","year":"2018","journal-title":"Haemophilia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/hae.14172","article-title":"Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET","volume":"26","author":"Coppola","year":"2020","journal-title":"Haemophilia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1055\/a-1127-6476","article-title":"Practical Guidance of the GTH Haemophilia Board on the Use of Emicizumab in Patients with Haemophilia A","volume":"40","author":"Holstein","year":"2020","journal-title":"Hamostaseologie"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"w20422","DOI":"10.4414\/smw.2020.20422","article-title":"Management of bleeding events and invasive procedures in patients with haemophilia A without inhibitors treated with emicizumab","volume":"150","author":"Fontana","year":"2020","journal-title":"Swiss Med. Wkly."},{"key":"ref_9","unstructured":"National Hemophilia Foundation (2023, February 27). Masac Document 268\u2014Recommendation on the Use and Management of Emicizumab-Kxwh (Hemlibra\u00ae) for Hemophilia a with and without Inhibitors. Available online: https:\/\/www.hemophilia.org\/sites\/default\/files\/document\/files\/268_Emicizumab.pdf."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/hae.14551","article-title":"Managing invasive procedures in haemophilia patients with limited resources, extended half-life concentrates or non-replacement therapies in 2022","volume":"28","author":"Mancuso","year":"2022","journal-title":"Haemophilia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1182\/bloodadvances.2022007458","article-title":"Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: Experience from the HAVEN 1-4 studies","volume":"6","author":"Peyvandi","year":"2022","journal-title":"Blood Adv."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Castaman, G., Windyga, J., Alzahrani, H., Robson, S., Sanabria, F., Howard, M., and Jim\u00e9nez-Yuste, V. (2021, January 11\u201314). Surgical Experience from the Phase Iiib Stasey Trial of Emicizumab Prophylaxis in Persons with Hemophilia a (Pwha) with Fviii Inhibitors: Final Analysis. Proceedings of the 63rd ASH Annual Meeting and Exposition, Atlanta, GA, USA. Oral presentation #344.","DOI":"10.1182\/blood-2021-145890"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/hae.14005","article-title":"Real-world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures","volume":"26","author":"McCary","year":"2020","journal-title":"Haemophilia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/hae.14212","article-title":"Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real-world experience from a large comprehensive treatment centre in the US","volume":"27","author":"Lewandowska","year":"2021","journal-title":"Haemophilia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/hae.14318","article-title":"Emicizumab prophylaxis: Prospective longitudinal real-world follow-up and monitoring","volume":"27","author":"Barg","year":"2021","journal-title":"Haemophilia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/hae.13877","article-title":"Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors","volume":"26","author":"Ebbert","year":"2020","journal-title":"Haemophilia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/hae.12518","article-title":"Safety and efficacy of turoctocog alfa (NovoEight\u00ae) during surgery in patients with haemophilia A: Results from the multinational guardian\u2122 clinical trials","volume":"21","author":"Santagostino","year":"2015","journal-title":"Haemophilia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e371","DOI":"10.1111\/hae.12212","article-title":"Cataract surgery in haemophilia","volume":"19","author":"Bijlsma","year":"2013","journal-title":"Haemophilia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/hae.14674","article-title":"Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A\u2014A modified Delphi consensus by the ADVANCE Working Group","volume":"29","author":"Klamroth","year":"2023","journal-title":"Haemophilia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"E549","DOI":"10.1111\/hae.14305","article-title":"Successful emicizumab prophylaxis during dual antiplatelet therapy for insertion of drug-eluting stents after acute coronary syndrome: A case report","volume":"27","author":"Nagao","year":"2021","journal-title":"Haemophilia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/hae.14679","article-title":"Emicizumab dose up-titration in case of suboptimal bleeding control in people with haemophilia A","volume":"29","author":"Schmitt","year":"2023","journal-title":"Haemophilia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/bloodadvances.2019001060","article-title":"Total knee replacement with and without emicizumab: A unique comparison of perioperative management","volume":"4","author":"Evans","year":"2020","journal-title":"Blood Adv."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/bloodadvances.2019000849","article-title":"Laboratory monitoring of hemophilia A treatments: New challenges","volume":"4","author":"Lenting","year":"2020","journal-title":"Blood Adv."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"20406207211040345","DOI":"10.1177\/20406207211040345","article-title":"Challenges of biological monitoring in a hemophilia A patient without inhibitors on emicizumab undergoing major orthopedic surgery: A case report","volume":"12","author":"Guillaume","year":"2021","journal-title":"Ther. Adv. Hematol."}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/15\/4\/62\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:15:24Z","timestamp":1760130924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/15\/4\/62"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["hematolrep15040062"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep15040062","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,1]]}}}